UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
eMagin Corporation
----------------------------------
(Name of Issuer)
Common Stock
----------------------------------
(Title of Class of Securities)
29076N 10 7
----------------------------------
(CUSIP Number)
December 31, 2002
----------------------------------
(Date of Event Which Requires Filing of This Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Page 1 of 4 pages
------------------------- --------------------
CUSIP No. 29076N 10 7 13G Page 2 of 4 Pages
------------------------- --------------------
----------- --------------------------------------------------------------------
1
NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO(S). OF ABOVE PERSON(S) (ENTITIES ONLY)
Mortimer D. Sackler, M.D.
----------- --------------------------------------------------------------------
2
CHECK THE APPROPRIATE BOX IF A MEMBEROF A GROUP (a) [ ]
(See Instructions) (b) [ ]
----------- --------------------------------------------------------------------
3
SEC USE ONLY
----------- --------------------------------------------------------------------
4
CITIZENSHIP OR PLACE OF ORGANIZATION
Austrian
----------------------------- ----- --------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
-0-
SHARES
----- --------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
-0-
OWNED BY
----- --------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER
-0-
REPORTING
----- --------------------------------------------
PERSON 8 SHARED DISPOSITIVE POWER
-0-
WITH:
----------- --------------------------------------------------------------------
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,763,781*
----------- --------------------------------------------------------------------
10
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(See Instructions) [ ]
----------- --------------------------------------------------------------------
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.8%
----------- --------------------------------------------------------------------
12
TYPE OF REPORTING PERSON (See Instructions)
IN
----------- --------------------------------------------------------------------
-------------------
* Includes shares beneficially owned indirectly through grantor trusts and
holding companies. Aggregate amount beneficially owned includes shares of the
Issuer's Common Stock that will be issued upon the conversion of 9% Secured
Convertible Notes (the "Notes"), dated November 27, 2001 and January 14, 2002,
as amended, and upon exercise of Stock Purchase Warrants, dated June 11, 1996,
March 16, 2000, November 27, 2001, January 14, 2002 and February 28, 2002, as
amended. This figure does not include shares which may be issuable upon
conversion of interest which may accrue from and after the date of issuance of
the Notes until such conversion.
Page 2 of 4 pages
Item 1.
(a) Name of Issuer: eMagin Corporation
(b) Address of Issuer's Principal Executive Offices:
2070 Route 52
Hopewell Junction, New York 12533
Item 2.
(a) Name of Person Filing: Mortimer D. Sackler, M.D.
(b) Address of Principal Business Office or, if none, Residence:
67 Chester Square
London SW1W 9DU, England
(c) Citizenship: Austrian
(d) Title of Class of Securities: Common Stock
(e) CUSIP Number: 29076N 10 7
Item 3. If this statement is filed pursuant toss.ss.240.13d-1(b), or
240.13d-2(b) or (c), check whether the person filing is a:
Not applicable
Item 4. Ownership
Provide the following information regarding the aggregate number and
percentage of the class of securities of the issuer identified in Item 1.
(a) Amount Beneficially Owned: 2,763,781*
(b) Percent of Class: 8.8%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: -0-
(ii) Shared power to vote or to direct the vote: -0-
(iii) Sole power to dispose or to direct the disposition of:
-0-
(iv) Shared power to dispose or to direct the disposition
of: -0-
Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following ?. Not
Applicable
Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable
Item 7. Identification and Classification of the Subsidiary Which Acquired the
Security Being Reported on by the Parent Holding Company or Control
Person
Not applicable
Item 8. Identification and Classification of Members of the Group
Not applicable
-------------------
* Includes shares beneficially owned indirectly through grantor trusts and
holding companies. Aggregate amount beneficially owned includes shares of the
Issuer's Common Stock that will be issued upon the conversion of 9% Secured
Convertible Notes (the "Notes"), dated November 27, 2001 and January 14, 2002,
as amended, and upon exercise of Stock Purchase Warrants, dated June 11, 1996,
March 16, 2000, November 27, 2001, January 14, 2002 and February 28, 2002, as
amended. This figure does not include shares which may be issuable upon
conversion of interest which may accrue from and after the date of issuance of
the Notes until such conversion.
Page 3 of 4 pages
Item 9. Notice of Dissolution of a Group
Not applicable
Item 10. Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
February 6, 2003
------------------------------------------
Date
/s/ Mortimer D. Sackler, M.D.
------------------------------------------
Signature
Mortimer D. Sackler, M.D.
------------------------------------------
Name/Title
Page 4 of 4 pages